Bleeding solution

More than a hundred-thousand lives could be saved each year if a readily available blood-clotting drug were administered to people who had suffered serious bleeding injuries or with surgical complications. Tranexamic acid (TXA), an off-patent drug, inhibits clot breakdown, and while some research suggests it increases the risk of cardiac arrest, stroke, and pulmonary thrombosis, the benefits in terms of controlling critical bleeding quickly might offset this risk. Indeed, the CRASH-2 trial, a large, randomized trial with more than 20,000 adult patients in 274 hospitals across 40 countries, showed no evidence of adverse effects caused by clotting.